S&P 500   3,838.29
DOW   31,092.26
QQQ   322.54
S&P 500   3,838.29
DOW   31,092.26
QQQ   322.54
S&P 500   3,838.29
DOW   31,092.26
QQQ   322.54
S&P 500   3,838.29
DOW   31,092.26
QQQ   322.54
Log in

Akebia Therapeutics Stock Forecast, Price & News

+0.01 (+0.32 %)
(As of 01/20/2021 11:19 AM ET)
Today's Range
Now: $3.15
50-Day Range
MA: $2.99
52-Week Range
Now: $3.15
Volume101,940 shs
Average Volume5.74 million shs
Market Capitalization$455.30 million
P/E RatioN/A
Dividend YieldN/A
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Akebia Therapeutics logo


Overall MarketRank

1.78 out of 5 stars

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:AKBA



Sales & Book Value

Annual Sales$335 million
Book Value$3.32 per share


Net Income$-279,660,000.00
Net Margins-126.86%


Market Cap$455.30 million
Next Earnings Date3/9/2021 (Estimated)
+0.01 (+0.32 %)
(As of 01/20/2021 11:19 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AKBA News and Ratings via Email

Sign-up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions

How has Akebia Therapeutics' stock price been impacted by Coronavirus?

Akebia Therapeutics' stock was trading at $6.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AKBA shares have decreased by 54.0% and is now trading at $3.19.
View which stocks have been most impacted by COVID-19

Is Akebia Therapeutics a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Akebia Therapeutics stock.
View analyst ratings for Akebia Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Akebia Therapeutics?

Wall Street analysts have given Akebia Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Akebia Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Akebia Therapeutics' next earnings date?

Akebia Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Akebia Therapeutics

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) released its quarterly earnings results on Tuesday, November, 10th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.25. The biopharmaceutical company earned $59.99 million during the quarter, compared to analysts' expectations of $76.12 million. Akebia Therapeutics had a negative net margin of 126.86% and a negative return on equity of 68.51%.
View Akebia Therapeutics' earnings history

What price target have analysts set for AKBA?

7 brokerages have issued twelve-month price targets for Akebia Therapeutics' stock. Their forecasts range from $3.00 to $18.00. On average, they anticipate Akebia Therapeutics' share price to reach $10.29 in the next twelve months. This suggests a possible upside of 222.4% from the stock's current price.
View analysts' price targets for Akebia Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Akebia Therapeutics' key competitors?

What other stocks do shareholders of Akebia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T).

Who are Akebia Therapeutics' key executives?

Akebia Therapeutics' management team includes the following people:
  • Mr. John P. Butler MBA, CEO, Pres & Director (Age 56, Pay $1.02M)
  • Mr. Michel Dahan, Sr. VP & COO (Age 41, Pay $567.57k)
  • Ms. Nicole R. Hadas, Sr. VP, Chief Legal Officer & Sec. (Age 47, Pay $497.37k)
  • Mr. Jason A. Amello, Exec. Officer (Age 52, Pay $578.05k)
  • Mr. Dell Faulkingham, Sr. VP & Chief Commercial Officer (Age 47, Pay $615.74k)
  • Mr. David A. Spellman, Sr. VP, CFO & Treasurer (Age 43)
  • Ms. Kristen K. Sheppard J.D., Esq., VP of Investor Relations
  • Mr. Douglas Jermasek, VP of Marketing & Strategy
  • Ms. Tamara Dillon, Sr. VP of HR
  • Dr. Karen L. Tubridy, Sr. VP & Chief Devel. Officer (Age 58)

What is Akebia Therapeutics' stock symbol?

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

How do I buy shares of Akebia Therapeutics?

Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Akebia Therapeutics' stock price today?

One share of AKBA stock can currently be purchased for approximately $3.19.

How big of a company is Akebia Therapeutics?

Akebia Therapeutics has a market capitalization of $461.08 million and generates $335 million in revenue each year. The biopharmaceutical company earns $-279,660,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Akebia Therapeutics employs 358 workers across the globe.

What is Akebia Therapeutics' official website?

The official website for Akebia Therapeutics is www.akebia.com.

How can I contact Akebia Therapeutics?

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]

This page was last updated on 1/20/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.